{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(2)"],"submitter":["Celik S"],"pubmed_abstract":["<b>Background/Objectives</b>: Eltrombopag, a thrombopoietin receptor agonist, is widely used in the treatment of relapsed or refractory (R/R) immune thrombocytopenia (ITP). This study aimed to compare the efficacy, safety, and tolerability of generic eltrombopag (Rompag<sup>®</sup>) with original eltrombopag (Revolade<sup>®</sup>) in adult patients with R/R ITP. <b>Methods</b>: In this prospective, multicenter study conducted at 10 centers, 104 adult ITP patients were followed for at least 3 months. A total of 35 (33.7%) patients received Rompag<sup>®</sup> and 69 (66.3%) received Revolade<sup>®</sup>. The primary endpoint was platelet (PLT) response, defined as achieving a PLT count ≥50 × 10<sup>9</sup>/L and at least a twofold increase from baseline, without the need for rescue therapy o"],"journal":["Journal of clinical medicine"],"pagination":["634"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12841940"],"repository":["biostudies-literature"],"pubmed_title":["Original Versus Generic Eltrombopag in Patients with Immune Thrombocytopenia: A Prospective Multi-Center Experience on Efficacy and Safety."],"pmcid":["PMC12841940"],"pubmed_authors":["Selim C","Celik S","Kırcalı E","Senturk Yıkılmaz A","Demircan V","Ciftciler R","Kurt Yuksel M","Karabulut ZT","Yıldız A","Pınar IE","Eroglu Kucukdiler AH","Acar NG","Yaman S","Keskin D","Acar IH"],"additional_accession":[]},"is_claimable":false,"name":"Original Versus Generic Eltrombopag in Patients with Immune Thrombocytopenia: A Prospective Multi-Center Experience on Efficacy and Safety.","description":"<b>Background/Objectives</b>: Eltrombopag, a thrombopoietin receptor agonist, is widely used in the treatment of relapsed or refractory (R/R) immune thrombocytopenia (ITP). This study aimed to compare the efficacy, safety, and tolerability of generic eltrombopag (Rompag<sup>®</sup>) with original eltrombopag (Revolade<sup>®</sup>) in adult patients with R/R ITP. <b>Methods</b>: In this prospective, multicenter study conducted at 10 centers, 104 adult ITP patients were followed for at least 3 months. A total of 35 (33.7%) patients received Rompag<sup>®</sup> and 69 (66.3%) received Revolade<sup>®</sup>. The primary endpoint was platelet (PLT) response, defined as achieving a PLT count ≥50 × 10<sup>9</sup>/L and at least a twofold increase from baseline, without the need for rescue therapy o","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-15T03:18:51.898Z","creation":"2026-06-15T03:08:51.149Z"},"accession":"S-EPMC12841940","cross_references":{"pubmed":["41598573"],"doi":["10.3390/jcm15020634"]}}